Precision IO Group to Showcase Epione® Robotic Platform and Remote Intervention Program at SRS Annual Meeting
Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, is set to showcase its latest advances in robotic and remote-enabled interventional oncology at the Society of Robotic Surgery (SRS) Annual Meeting in Hollywood, Florida, taking place from July 22 through July 26, 2026.
The company will exhibit at booth #325, where attendees will have the opportunity to learn more about the Epione® robotic ablation platform and Precision IO Group’s developing remote intervention program. The company’s participation will bring together leaders in interventional radiology, robotic surgery, medical technology, and investment to discuss the evolving role of robotics and artificial intelligence in minimally invasive cancer care.
Among the featured speakers will be Prof. Dr. Sean Tutton, MD, Professor of Radiology and Orthopedics, and Dr. Govindarajan Narayanan, MD, FSIR, Professor of Radiology and Chief of Interventional Oncology. Dr. Narayanan was the first physician to treat a patient with Epione in the United States.
Precision IO Group CEO Kurt Azarbarzin has also been invited to participate as a panelist in the Investor Session at the meeting.
The company’s presence at the annual event comes as robotic technologies continue to expand beyond traditional surgical applications. In interventional oncology, robotics and artificial intelligence are increasingly being explored as tools to improve the planning, targeting, and delivery of minimally invasive procedures.
Combining Robotics, Artificial Intelligence, and Interventional Oncology
Precision IO Group was formed through the combination of Quantum Surgical and NeuWave Medical. The organization brings together expertise in medical devices, robotics, artificial intelligence, and minimally invasive cancer treatment.
Through the combination of these capabilities, Precision IO Group is focused on advancing technologies designed to support physicians treating tumors through percutaneous procedures.
The company’s Epione platform is at the center of its presentation at the SRS Annual Meeting. The robotic system combines CT-guided planning, AI-assisted targeting, and robotic needle guidance to help physicians access and treat tumors that may be difficult to reach.
The platform is designed to support percutaneous tumor ablation through a single skin puncture. By integrating imaging, planning, artificial intelligence, and robotic guidance, Epione aims to help clinicians approach complex cases with greater consistency and precision.
Tumor ablation is a minimally invasive treatment approach used to destroy targeted tumors. Depending on the clinical situation, physicians may use different energy-based techniques to destroy cancerous tissue. The ability to accurately plan the trajectory of the treatment instrument and reach the intended target is a critical component of the procedure.
Complex tumor locations can present challenges because of the position of the tumor, surrounding anatomy, and the need to avoid critical structures. Robotic assistance may help physicians plan and execute trajectories in a structured and repeatable manner.
Presenting Real-World Clinical Experience
At the SRS Annual Meeting, interventional radiology leaders will discuss the clinical use of Epione and share their experience with the robotic platform.
Dr. Narayanan has been closely involved in the adoption of Epione in the United States. As the first physician to treat a patient with the system in the country, his experience provides insight into the integration of robotic assistance into interventional oncology workflows.
He has described robotic assistance as becoming a routine part of how he plans and performs percutaneous ablation procedures.
“I performed the first Epione procedure in the United States three years ago, and robotic assistance is now a routine part of how I plan and perform percutaneous ablations,” said Dr. Narayanan.
His presentation at the meeting will focus on the next challenge facing specialized cancer care: geographic access.
Specialized interventional oncology expertise is often concentrated in a limited number of major medical centers. Patients living far from these institutions may face challenges when seeking access to physicians with extensive experience in complex tumor ablation procedures.
Precision IO Group believes that remote intervention technologies could eventually help address this geographic gap.
Developing a Remote Intervention Program
In addition to presenting the Epione robotic platform, Precision IO Group will discuss its remote intervention program, which is currently under development.
The program is intended to explore how telerobotics and remote-enabled capabilities could help extend specialized interventional oncology expertise beyond the medical centers where it is currently concentrated.
The initial focus of the program is remote trajectory planning and results assessment using Epione. Through these capabilities, the company is exploring ways for specialists to support procedures and evaluate outcomes remotely.
The broader goal is to reduce geographic barriers to expert cancer care.
Under the concept being developed by Precision IO Group, a patient could potentially receive treatment at a local healthcare facility while specialized experts in another location provide remote support for elements of the procedure.
Such an approach could help connect patients and physicians across geographic distances. However, the company emphasizes that remote intervention capabilities remain in development and are not currently available for commercial use.
Addressing the Geographic Concentration of Expertise
The availability of specialized cancer care can vary significantly depending on a patient’s location. While major academic medical centers and specialized hospitals may offer advanced interventional oncology services, patients in rural or underserved regions may have limited access to experienced specialists.
Traveling long distances for care can create financial, logistical, and emotional challenges for patients and their families.
Remote intervention technologies could potentially provide a new model for delivering specialized expertise. By combining robotics, advanced imaging, artificial intelligence, and secure communication systems, remote platforms may eventually allow specialists to participate in procedures without being physically present at the same location.
Precision IO Group’s program is focused on developing the technological foundation needed to explore this model.
The company’s initial work on remote trajectory planning and results assessment represents a step toward creating a more connected approach to interventional oncology. Remote specialists could potentially review imaging data, assist with treatment planning, and assess procedural results.
Kurt Azarbarzin, CEO of Precision IO Group, said the company’s objective is to extend access to specialized cancer care.
“It’s an honor to be at SRS alongside two interventional radiology leaders who will share firsthand how Epione has improved their day-to-day practice to reach more patients,” Azarbarzin said.
“Today, subspecialty expertise in tumor ablation is concentrated in a small number of centers globally. Through our remote intervention program and AI-enabled planning on Epione, our goal is to continue to extend access to cancer care for patients everywhere,” he added.
AI-Enabled Planning for Complex Procedures
Artificial intelligence is an important component of the Epione platform and Precision IO Group’s broader technology strategy.
In interventional oncology, AI can support the analysis of medical images and assist with treatment planning. The ability to identify and analyze relevant anatomy can help physicians evaluate possible treatment trajectories and plan procedures more efficiently.
Epione combines AI-assisted planning with robotic needle guidance and CT-based imaging. This integrated approach is designed to help clinicians evaluate tumor location, plan access routes, and guide the treatment instrument toward the intended target.
For complex cases, the ability to analyze multiple factors simultaneously may help physicians develop more structured treatment plans.
The use of robotics may also provide consistency during the execution of a planned trajectory. While physicians remain responsible for clinical decision-making, robotic systems can provide technological support for positioning and guidance.
The combination of AI and robotics reflects a broader trend in healthcare toward technology-assisted procedures. As medical imaging becomes increasingly sophisticated, healthcare companies are developing systems that can help clinicians translate imaging data into procedural action.
Robotics Beyond the Operating Room
The SRS Annual Meeting traditionally brings together experts in robotic-assisted surgery and related technologies. Precision IO Group’s participation highlights the expanding role of robotics in interventional procedures outside the traditional operating room.
Robotic technologies are increasingly being applied in areas such as interventional radiology, oncology, and image-guided procedures.
These applications differ from conventional surgical robotics because many procedures are performed through small skin punctures rather than large incisions. The objective is to use technology to improve the planning and accuracy of minimally invasive interventions.
In the case of Epione, the system is designed specifically to support tumor ablation procedures. By integrating CT imaging, AI planning, and robotic guidance, the platform aims to help physicians manage the technical complexity associated with targeting tumors.
The company believes that these technologies could be particularly valuable as clinicians seek minimally invasive options for patients who may not be candidates for traditional surgery or who require alternative treatment approaches.
Future Possibilities for Telerobotics
The development of remote intervention capabilities represents a potentially significant evolution in the use of medical robotics.
Remote healthcare technologies have expanded rapidly in recent years, particularly in areas such as virtual consultations, remote monitoring, and digital clinical collaboration. However, remote participation in physical procedures presents additional technical and regulatory challenges.
Precision IO Group’s remote intervention program is focused on exploring how robotics and digital connectivity could be used to support specialized procedures across distances.
The initial focus on remote trajectory planning and results assessment provides a practical starting point. These capabilities may allow specialists to contribute to a procedure without requiring complete remote control of every aspect of the intervention.
As the technology develops, future applications could potentially expand. However, significant technical, clinical, regulatory, and infrastructure considerations will need to be addressed before remote intervention becomes widely available.
For now, Precision IO Group is continuing development work and emphasizes that the program is not commercially available.
Building a More Connected Model of Cancer Care
The company’s participation at the SRS Annual Meeting reflects its broader strategy of combining robotics, artificial intelligence, and remote-enabled technologies to advance minimally invasive cancer care.
The Epione platform is designed to help physicians perform image-guided tumor ablation with robotic assistance. The remote intervention program is intended to explore how specialized expertise can be extended beyond major medical centers.
Together, these initiatives reflect a vision of a more connected model of healthcare in which technology helps bridge geographic barriers.
For patients, improved access to specialized care could potentially reduce the need to travel long distances. For healthcare providers, remote collaboration could help connect local teams with experts in complex procedures.
The success of this model will depend on continued technological development, clinical validation, regulatory progress, and healthcare system integration.
At the 2026 Society of Robotic Surgery Annual Meeting, Precision IO Group will highlight both the current clinical applications of the Epione robotic ablation platform and its future vision for remote intervention.
The company’s presentations will provide attendees with an opportunity to learn about the use of robotic assistance in percutaneous tumor ablation and the potential role of AI-enabled planning in complex interventional oncology procedures.
The participation of experienced physicians, including Dr. Sean Tutton and Dr. Govindarajan Narayanan, will bring clinical perspectives to the discussion. Dr. Narayanan’s experience as the first physician to treat a patient with Epione in the United States will provide insight into how robotic technology can become part of everyday interventional oncology practice.
Meanwhile, Precision IO Group’s remote intervention program represents the company’s longer-term effort to address the geographic concentration of specialized expertise.
As robotics and artificial intelligence continue to evolve, their role in cancer treatment may expand beyond improving procedural precision. These technologies could also help connect specialists, healthcare institutions, and patients across geographic boundaries.
Through Epione and its developing remote intervention program, Precision IO Group is working toward a future in which advanced robotic and AI-enabled tools support more accessible, connected, and minimally invasive cancer care.
Source link: https://www.businesswire.com/
